# A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis

> **NCT06218290** · PHASE2 · COMPLETED · sponsor: **Unicycive Therapeutics, Inc** · enrollment: 106 (actual)

## Conditions studied

- Chronic Kidney Disease Requiring Chronic Dialysis

## Interventions

- **DRUG:** Oxylanthanum Carbonate

## Key facts

- **NCT ID:** NCT06218290
- **Lead sponsor:** Unicycive Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-15
- **Primary completion:** 2024-05-29
- **Final completion:** 2024-05-29
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06218290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06218290, "A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06218290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*